Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
CAMBRIDGE, Mass. and BASEL, Switzerland, March 21, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced ... Biopharmaceuticals, FDA Enzyvant, Roivant Sciences, Farber Disease, enzyme replacement therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2019 Category: Pharmaceuticals Source Type: news

FDA Busts J & amp;J and Sientra Over Breast Implant Compliance
FDA busted two manufacturers of silicone gel-filled breast implants this week for failure to comply with post-approval study requirements. The agency sent warning letters to Irvine, CA-based Mentor Worldwide, a unit of Johnson & Johnson, and to Santa Barbara, CA-based Sientra for deficiencies in each company's post-approval study for silicone breast implant approvals. Breast implants have been a source of contention between patient advocacy groups, industry, and FDA for decades. Implants were banned from the U.S. market from 1992 to 2006, and the devices have been the cause of an ove...
Source: MDDI - March 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Agility in Rare Disease and Oncology Clinical Trials – Data...
Modular and adaptive clinical trials are rapidly expanding the ability of researchers to modify clinical trials based on emerging data, i.e. to make better decisions based on positive clinical...(PRWeb March 19, 2019)Read the full story at https://www.prweb.com/releases/agility_in_rare_disease_and_oncology_clinical_trials_data_management_new_webinar_hosted_by_xtalks/prweb16178993.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 19, 2019 Category: Pharmaceuticals Source Type: news

Cochrane's 30 under 30: Theresa Schmalfu ß
Cochrane is made up of  13,000 members and over 50,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Cochrane is an incredible community of people who all play their part in improving health and healthcare globally. We believe that by putting trusted evidence at the heart of health decisions we can achieve a world of improved health for all.  Many  of our contributors are young people working with Cochrane ...
Source: Cochrane News and Events - March 18, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Rare diseases prompted care in ancient times
(Source: ScienceNOW)
Source: ScienceNOW - March 14, 2019 Category: Science Authors: Curry, A. Tags: Anthropology, Epidemiology In Depth Source Type: news

Worrying side effects put damper on Alnylam ’s positive trial results
Alnylam Pharmaceuticals ’ new treatment for a rare disease has been shown to be effective — but analysts are now worried about its safety. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 6, 2019 Category: Pharmaceuticals Source Type: news

After trial success, Alnylam plans to seek FDA approval for 2nd drug
Less than a year after receiving the first-ever FDA approval for a gene-silencing drug, Alnylam Pharmaceuticals Inc. now plans pushing another to market, announcing Wednesday morning that its second treatment succeeded in a late-stage trial. Cambridge-based Alnylam (Nasdaq: ALNY) develops so-called RNA interference, or RNAi, drugs that silence disease-creating genes. Its first product, the rare disease drug Onpattro, was the first such treatment to be approved by the FDA and launched last year.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 6, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Namibia: Rare Disease Patients Need Support
[New Era] There is a need to create awareness and on the extent of psychological and financial support to people suffering from rare diseases. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 5, 2019 Category: African Health Source Type: news

A common genetic signature has been discovered among three cancer prone rare skin diseases
(Universidad Carlos III de Madrid) A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid (UC3M), Marcela del R í o, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre (Initials in Spanish: CIBERER-- ISCIII) and Fundaci ó n Jim é nez D í az has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum. In the near future, these findings will allow efficient and safe evidence-based therapeutic approaches. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 4, 2019 Category: International Medicine & Public Health Source Type: news

Guest post: Hearing from patients on Rare Disease Day
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. In honor of Rare Disease Day, we sat down with Paul Melmeyer of the National Organization for Rare Disorders (NORD) to discuss rare diseases, how we can spur innovation and what c...
Source: The Catalyst - February 28, 2019 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases FDA Source Type: news

Finding New Uses For Old Drugs - A Lifeline For Rare Disease Patients
Discovering new uses for old medicines, called drug repurposing, offers hope of treatments for thousands of patients. It is also faster and less expensive than traditional drug development. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 28, 2019 Category: Pharmaceuticals Authors: Judy Stone, Contributor Source Type: news

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Today is Rare Disease Day, an annual reminder of the incredible community of patients living with a rare disease. In the U.S., rare diseases areclassified as conditions that affect fewer than 200,000 people, and according to theNational Institutes of Health (NIH), 10 percent of the U.S. population currently lives with a rare disease. To date, researchers have identified more than 7,000 rare diseases,85 percent of which are considered life-threatening, and the biopharmaceutical industry is committed to finding treatments for these 30 million patients living with rare diseases. We ’ve made important progress towar...
Source: The Catalyst - February 28, 2019 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Rare Diseases FDA PDUFA Source Type: news

On Rare Disease Day, Alnylam launches patient advocacy grant program
In honor of Rare Disease Day, Alnylam Pharmaceuticals has launched a grant program for patients advocacy groups increasing awareness of two uncommon diseases. Alnylam (Nasdaq: ALNY) announced the first seven recipients of its new Advocacy for Impact Grants program Thursday. Through the program, the drug company will give out $248,000 to organizations focused on the rare diseases acute hepatic porphyria and ATTR amyloidosis. The activities of those grou ps include advocating for better diagnosis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 28, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Rare Disease Day- 28 February 2019
Rare Disease Day is celebrated on the last day of February every year. The purpose of the day is to raise awareness amongst not only the rare disease... The post Rare Disease Day- 28 February 2019 appeared first on Ashfield Healthcare. (Source: Ashfield Healthcare News)
Source: Ashfield Healthcare News - February 28, 2019 Category: Pharmaceuticals Authors: Ashfield Healthcare Communications Source Type: news

New affiliation to advance therapies for rare diseases
(University Hospitals Cleveland Medical Center) The University of Oxford and University Hospitals in Cleveland, Ohio, announced a multi-year affiliation to establish a global center for rare diseases. The Oxford-Harrington Rare Disease Centre will bring together the capabilities, resources and expertise of both institutions to deliver new treatments for rare diseases, for which therapeutic options are lacking. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2019 Category: International Medicine & Public Health Source Type: news

Healx Pushing New Drug Development Model in Rare Diseases with Barth...
The announcement comes on World Rare Disease Day, an annual global awareness initiative designed to bring attention of rare diseases to the general public and policymakers.(PRWeb February 28, 2019)Read the full story at https://www.prweb.com/releases/healx_pushing_new_drug_development_model_in_rare_diseases_with_barth_syndrome_foundation/prweb16135183.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 28, 2019 Category: Pharmaceuticals Source Type: news

Rare Genomics Institute Demonstrates the Power of Genomenon's...
Genomenon's Mastermind Genomic Search Engine Connects Patient with Rare Disease Diagnosis.(PRWeb February 28, 2019)Read the full story at https://www.prweb.com/releases/rare_genomics_institute_demonstrates_the_power_of_genomenon_s_ai_based_technology_in_diagnosis/prweb16138501.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 28, 2019 Category: Pharmaceuticals Source Type: news

Families share stories of rare disease struggle
Rare Disease Day is meant to bring awareness to the more than 7,000 rare diseases affecting thousands of people in the U.S. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 27, 2019 Category: Consumer Health News Source Type: news

Mom Blazes Path to Cure for Son ’s Rare Disease
Although the FDA has approved 400 treatments for rare diseases, progress toward finding cures for the 7,000 remains slow (Source: WebMD Health)
Source: WebMD Health - February 27, 2019 Category: Consumer Health News Source Type: news

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
PALO ALTO, Calif., Feb. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced t... Biopharmaceuticals, Personnel Eiger BioPharmaceuticals, lonafarnib, Hepatitis Delta Virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2019 Category: Pharmaceuticals Source Type: news

Are low-priced drugs becoming an endangered species?
A new report by Canada's drug price regulator warns that new medicines are becoming increasingly expensive. Almost half of the new drugs coming on the market in 2016 and 2017 were "orphan" drugs aimed at treating rare diseases, with the average cost per patient approaching $1 million a year. (Source: CBC | Health)
Source: CBC | Health - February 26, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Roche to buy Spark Therapeutics
Roche Holding has entered a definitive merger agreement with Spark Therapeutics, as the Swiss drugmaker seeks to expand its ability to treat rare diseases through gene therapies, as well as build its hemophilia portfolio. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 25, 2019 Category: Pharmaceuticals Source Type: news

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Uncounselled, Unreferred And Untreated: The Urgency Of IVF And OncoFertility
Watch the interplay between the huge insurer/hospital system duopoly and the emerging IVF-only ecosystem that is being created to accommodate large employers'needs to provide IVF coverage , as that coverage begins to include collaboration with oncology and hematology and rare disease centers. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 24, 2019 Category: Pharmaceuticals Authors: David Sable, Contributor Source Type: news

A4. Patients & caregivers can share their stories and experiences living with a rare disease directly with #FDA through Rare Disease Listening Session pilot program. Learn more: https://go.usa.gov/xEECU   #NIHchatpic.twitter.com/mVptIt3bTI
A4. Patients & caregivers can share their stories and experiences living with a rare disease directly with #FDA through Rare Disease Listening Session pilot program. Learn more: https://go.usa.gov/xEECU  #NIHchat pic.twitter.com/mVptIt3bTI (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - February 22, 2019 Category: Medical Devices Authors: ( at FDAPatientinfo) Source Type: news

A1. #FDA has many avenues in which patients and caregivers can share the challenges of living with a rare disease with the Agency. Learn more https://youtu.be/IKOPEMQYdkI   #NIHchatpic.twitter.com/N8ZTj5gVV6
A1. #FDA has many avenues in which patients and caregivers can share the challenges of living with a rare disease with the Agency. Learn more https://youtu.be/IKOPEMQYdkI  #NIHchat pic.twitter.com/N8ZTj5gVV6 (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - February 22, 2019 Category: Medical Devices Authors: ( at FDAPatientinfo) Source Type: news

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry. (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
CAMBRIDGE, Massachusetts and BASEL, Switzerland, Feb. 21, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, today announced the appointme... Biopharmaceuticals, Personnel Enzyvant, immunodeficiency (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 21, 2019 Category: Pharmaceuticals Source Type: news

Microsoft, Takeda, Eurordis take on rare diseases in children with report, pilots
The three companies announced a slew of pilots employing  machine learning, collaborative digital tools and blockchain technology.  (Source: mobihealthnews)
Source: mobihealthnews - February 20, 2019 Category: Information Technology Source Type: news

People with rare diseases get 'unequal treatment' from 'inflexible' NHS drug regulator, warns report
A study by MAP BioPharma found only 13 per cent of rare disease medicines made it through The National Institute for Health and Care Excellence (NICE) assessments. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2019 Category: Consumer Health News Source Type: news

Ultragenyx CMO helms rare disease team
In the latest step in a long career, Dr. Camille Bedrosian has taken on the role of chief medical officer at Ultragenyx in Novato. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 14, 2019 Category: Biotechnology Authors: Nathan Falstreau Source Type: news

Ultragenyx CMO helms rare disease team
Dr. Camille Bedrosian has spent much of her career in the biotech sector, primarily working with rare diseases. “It’s a different level of commitment and tenacity, not taking no for an answer to solve a problem,” she said. “It’s been a little over two decades for me, and I’ve always been in rare disease.” Bedrosian previously helped to build a development group at Alexion Pharmaceuticals Inc. working on small molecules for oncology, focusing on rare cancers such as sarcoma. Camille… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 14, 2019 Category: Pharmaceuticals Authors: Nathan Falstreau Source Type: news

Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the Food and Drug Administration, Division of Neurology (the Division), has accepted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 14, 2019 Category: Drugs & Pharmacology Source Type: news

Mendelian helps NHS to speed up rare disease diagnosis
Mendelian, a UK healthtech startup,  has received a £500,000 grant from Innovate UK to build platforms that will help GPs to identify NHS patients with potentially rare or hard-to-diagnose conditions and diseases more quickly. (Source: mobihealthnews)
Source: mobihealthnews - February 13, 2019 Category: Information Technology Source Type: news

Catalyst Pharma sees net price of drug, once free, topping $300,000
Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts. (Source: Reuters: Health)
Source: Reuters: Health - February 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Patients to share personal journeys at NIH Rare Disease Day events
Connect with patients about navigating life with a rare disease. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 11, 2019 Category: American Health Source Type: news

How Advanced Therapies are Changing the Landscape of Rare Disease, New...
After years of innovative research, advanced therapies are dramatically changing the way patients are treated for a wide variety of diseases – particularly for patients with rare diseases and orphan...(PRWeb February 11, 2019)Read the full story at https://www.prweb.com/releases/how_advanced_therapies_are_changing_the_landscape_of_rare_disease_new_webinar_hosted_by_xtalks/prweb16092284.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 11, 2019 Category: Pharmaceuticals Source Type: news

Price of life-changing drug for college senior's rare disease hiked from free to $375,000
Will Schuller would be confined to a wheelchair - if not worse - without medication for his rare autoimmune disease, LEMS. The drug was free, but a drug company hiked the price to $375K. (Source: the Mail online | Health)
Source: the Mail online | Health - February 9, 2019 Category: Consumer Health News Source Type: news

When sequencing fails to pinpoint a rare disease
(American Society for Biochemistry and Molecular Biology) Genomics fails to diagnose up to half of patients who are tested. German scientists tackled the problem in a recent study in the journal Molecular& Cellular Proteomics. Using a new neutrophil proteome database they made genetic diagnoses for children with severe congenital neutropenia whom typical sequencing had failed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2019 Category: International Medicine & Public Health Source Type: news

First US attempt to cure a rare disease with genome editing fails miserably 
Sangamo Therapeutics tried to cure two forms of a rare genetic disease using 'zinc finger' gene editing. They successfully changed the genome, but it didn't work to lessen or stop the diseases' effects. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2019 Category: Consumer Health News Source Type: news

First US attempt to cure a rare disease with genome editing fails miserably  
Sangamo Therapeutics tried to cure two forms of a rare genetic disease using 'zinc finger' gene editing. They successfully changed the genome, but it didn't work to lessen or stop the diseases' effects. (Source: the Mail online | Health)
Source: the Mail online | Health - February 7, 2019 Category: Consumer Health News Source Type: news

Aeglea aims to raise $60M for treating rare diseases
Aeglea BioTherapeutics Inc., an Austin-based biotechnology company developing treatments for rare genetic diseases and cancer, plans to raise $60 million with a new stock offering. The company on Feb. 5 agreed to sell 3.5 million shares of common stock to underwriters at $8 per share, plus pre-funded warrants to purchase up to 3.75 million more shares. Those underwriters will also have the option to buy up to 1,125,000 more shares. Aeglea (Nasdaq: AGLE) expects the offering to close Feb. 8 and… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 7, 2019 Category: American Health Authors: Will Anderson Source Type: news

Facing crackdown in Canada, drugmakers offered billions in price cuts
Canadian pharmaceutical industry lobby groups, in an effort to head off a planned crackdown on prescription drug prices, offered to give up $8.6 billion in revenue over 10 years, freeze prices or reduce the cost of treating rare diseases, Reuters reports. (Source: CBC | Health)
Source: CBC | Health - February 6, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Exclusive: Facing crackdown in Canada, drugmakers offered billions in price cuts
Canadian pharmaceutical industry lobby groups, in an effort to head off a planned crackdown on prescription drug prices, offered to give up C$8.6 billion ($6.6 billion) in revenue over 10 years, freeze prices or reduce the cost of treating rare diseases, according to interviews and documents seen by Reuters. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Zogenix Submits New Drug Application to U.S. Food & Drug Administration for Fintepla for the Treatment of Dravet Syndrome
EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S.... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 6, 2019 Category: Drugs & Pharmacology Source Type: news

Announcing 7 new GA4GH Driver Projects for 2019
(Global Alliance for Genomics and Health) GEnome Medical alliance Japan (GEM Japan), H3Africa, Swiss Personalised Health Network (SPHN), the Autism Sharing Initiative, EpiShare, EUCANCan, and the European Joint Programme on Rare Diseases (EJP RD) have been named 2019 GA4GH Driver Projects -- leading international genomic data initiatives that help develop and pilot standards for sharing data. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 4, 2019 Category: International Medicine & Public Health Source Type: news

Putting 2018 medicine approvals in context
Last year, the U.S. Food and Drug Administration ’s (FDA) Center for Drug Evaluation and Research (CDER)approved a record number of novel new medicines with 59 new molecular entities (NMEs). While medicine approval numbers vary each year, 2018 was a particularly exciting year for drug development. These novel approvals demonstrate biopharmaceutical research companies ’ continued commitment to developing innovative medicines and highlight the FDA and Commissioner Gottlieb’s commitment to strengthening the Agency’s human drug review program through ongoing implementation of the Prescription Drug User ...
Source: The Catalyst - January 23, 2019 Category: Pharmaceuticals Tags: New Era of Medicine FDA Rare Diseases PDUFA Research and Investment Source Type: news

50 cancer, rare disease drugs to get cheaper
The decision was taken at a high-level meeting with the Prime Minister ’s Office earlier this month. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 23, 2019 Category: Pharmaceuticals Source Type: news

How to Leverage eCOA for Improved Signal Detection in Pediatric & ...
High-quality data are critical when seeking to measure treatment outcomes, but this is especially true —and especially challenging—in rare disease trials where the stakes are high, the assessments are...(PRWeb January 23, 2019)Read the full story at https://www.prweb.com/releases/how_to_leverage_ecoa_for_improved_signal_detection_in_pediatric_rare_disorder_trials_new_webinar_hosted_by_xtalks/prweb16051350.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 23, 2019 Category: Pharmaceuticals Source Type: news